Dexamethasone QD
Small molecule
Dexamethasone QD is one of 11 small molecule programs targeting Pulmonary Edema. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Pulmonary Edema
#DrugCompanyPhaseTrials
1Diamox
TevaApproved
Isordil
AstraZenecaApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Nitrostat
VViatris Specialty LLC
Phase 2
Alka-Seltzer
AAbbott
Phase 2
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Viagra
VViatris Specialty LLC
Phase 1
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexamethasone QD. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- UUniversity of Zurich